Updated MARIPOSA Data Highlight Clinical Impact of Upfront Dual Inhibition in EGFR+ NSCLC
Upfront dual inhibition of EGFR and MET with amivantamab plus lazertinib reduces resistance and extends survival in EGFR‑mutated NSCLC compared with osimertinib.
The phase 3 MARIPOSA trial in EGFR‑mutated non‑small cell lung cancer shows that the combination of amivantamab (an EGFR/MET bispecific antibody) and lazertinib (a third‑generation EGFR TKI) significantly reduces the emergence of EGFR‑ and MET‑driven resistance mechanisms and prolongs overall survival compared with osimertinib monotherapy.
Demonstrating that combined EGFR and MET blockade can delay or prevent common resistance mutations (e.g., MET amplification, EGFR C797S) supports a shift from TKI monotherapy to a dual‑targeted first‑line strategy, potentially improving long‑term outcomes for patients with EGFR‑mutated lung cancer.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT